21
Oct
2009
Posted in I - Series A, Q - 3Q09, R - NORTH EAST, X - ADHD, X - CNS, XX - NY
Curemark (Rye, NY) a clinical-stage biopharma company focused on the treatment of neurological disease (autism and ADHD), clased a $6.5M Series A financing. Participants were not disclosed.